To evaluate the global economic differences in modern glioblastoma care, focusing on costs and cost-effectiveness of treatment regimens since the introduction of the Stupp protocol, which is critical for understanding economic viability.
Key Findings:
Glioblastoma treatment remains resource-intensive with high recurrence rates, with over 50% of patients experiencing recurrence within seven months.
Cost-effectiveness of modern therapies varies significantly across different healthcare systems, with some finding advanced technologies cost-effective while others do not.
The Stupp protocol is the gold standard, but the economic viability of new therapies needs further evaluation to determine their place in treatment.
Interpretation:
The review highlights the need for a systematic assessment of the economic implications of glioblastoma treatments globally, considering the diverse healthcare landscapes and their impact on treatment accessibility.
Limitations:
Potential bias in included studies due to retrospective designs, which may skew cost-effectiveness results.
Variability in cost reporting and methodologies across different countries, which complicates direct comparisons.
Conclusion:
A comprehensive understanding of the economic burden of glioblastoma management is essential for optimizing treatment strategies and resource allocation in various healthcare systems, and future research should focus on addressing identified gaps.
Baptist Health Foundation announced that it has received a $2 million donation from Anthony and Joyce Esernia to establish a new endowed chair at Baptist Health Miami Neuroscience Institute.
